Artificial intelligence (AI) is reshaping healthcare at an unprecedented pace, giving healthcare leaders more choices than ever before. In an article for Forbes, William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, offers a grounded perspective on how organizations can navigate this environment to make smart AI investment decisions.

“Chasing every new tool is neither practical nor sustainable, and investing in unproven or redundant tools risks draining resources without meaningful impact,” says Dr. Morice.

Studies show expanding use of AI across clinical documentation, imaging, and diagnostics. At the same time, the Food and Drug Administration is approving AI‑enabled medical devices at a record rate, and investment in AI‑focused companies continues to climb. Together, these trends are rapidly expanding the number of available tools, making it more difficult to determine where to invest. Dr. Morice encourages leaders to evaluate opportunities through clear criteria based on:

1. Organizational alignment
2. Clinical impact
3. Integration and scalability
4. Workflow optimization
5. Regulatory compliance and vendor reliability
6. Financial viability

Applying this structured approach helps organizations prioritize AI solutions that deliver measurable impact while avoiding costly distractions amid rapid innovation.

Read the full article for more details.